Stock NOVN NOVARTIS AG
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange
Other stock markets
 11:30:39 2024-12-06 am EST 		5-day change 1st Jan Change
89.81 CHF -0.63% Intraday chart for Novartis AG -3.71% +5.82%
Dec. 06 Swiss Market Index Ends Week Little Changed; Holcim Shares Down MT
Dec. 06 Novartis Reports 'Positive' Results From Phase 3 Study of Potential Blood Disorder Therapy MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Novartis Reports 'Positive' Results From Phase 3 Study of Potential Blood Disorder Therapy
Dec. 06
 MT
Novartis' Rare Blood Disorder Drug Improves Hemoglobin Levels in Phase 3b Trial
Dec. 06
 MT
New Phase IIIB data shows Novartis Fabhalta(R) improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy
Dec. 06
 DJ
Novartis Announces Positive Topline Results from APPULSE-PNH, a Phase IIIB Study Evaluating the Efficacy and Safety of Two-Daily Oral Monotherapy Fabhalta
Dec. 06
 CI
US Court Rejects Novartis' Appeal to Block Heart Failure Drug's Generic Version
Dec. 04
 MT
Novartis cannot block generic of best-selling heart drug, US appeals court says
Dec. 04
 RE
HSBC Downgrades Novartis to Reduce, Price Target is $95
Dec. 04
 MT
Sector Update: Health Care Stocks Slipping Late Afternoon
Dec. 02
 MT
Sector Update: Health Care Stocks Softer Monday Afternoon
Dec. 02
 MT
Sector Update: Health Care
Dec. 02
 MT
PTC Therapeutics Strikes Up to $2.9 Billion Licensing Deal With Novartis for Huntington's Disease Drug Candidate
Dec. 02
 MT
Sector Update: Health Care
Dec. 02
 MT
Olema Partners With Novartis for Clinical Trial of Potential Breast Cancer Drug, Launches $250 Million Stock, Warrant Placement
Dec. 02
 MT
PTC Therapeutics Shares Jump on Pact With Novartis
Dec. 02
 DJ
PTC Therapeutics Signs Exclusive Global License Deal With Novartis Unit for PTC518 Huntington's Disease Program; Shares Rise Premarket
Dec. 02
 MT
Novartis Wins EU Approval for Expanded Use of Kisqali in Breast Cancer Treatment
Nov. 27
 MT
Novartis' Early Breast Cancer Drug Gets Approval from EU Commission
Nov. 27
 MT
EU Commission Approves Novartis' Kisqali in Broad Population of Breast Cancer Patients
Nov. 27
 MT
Novartis Kisqali Receives European Commission Approval in A Broad Population of Patients with HR+/HER2- Early Breast Cancer at High Risk of Recurrence
Nov. 27
 CI
Octavian AG Lifts Price Target on Novartis, Maintains Hold Recommendation
Nov. 26
 MT
Novartis: to present data at annual meeting
Nov. 25
 CF
NOVARTIS : Stifel raises its target price for the share
Nov. 25
 CF
Novartis highlights new 96-week results from Phase III Scemblix(R) ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali(R) NATALEE trial at SABCS
Nov. 25
 DJ
Swiss Market Index Closes Higher; Pierer Mobility Shares Jump
Nov. 22
 MT
Health Care Climbs After Novartis Earnings - Health Care Roundup
Nov. 21
 DJ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NOVN Stock
  4. News Novartis AG
  5. Highlights